STTK Maintained by HC Wainwright & Co. -- Price Target Lowered to $14

HC Wainwright & Co. has maintained a 'Buy' rating for Shattuck Labs (STTK) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook due to the company's significant overvaluation, low profitability, and mixed insider sentiment. Despite developing innovative therapies, the stock is currently trading at $7.19 against a GF Value™ of $1.05, indicating a 584.8% overvaluation. Investors are advised to exercise caution given the financial challenges and insider selling trends.